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INTRODUCTION
Paget’s disease (PD) is an uncommon intraepithelial 
neoplasm first described by Sir James Paget in 1874 as 
nipple ulceration associated with an underlying breast 
carcinoma mass.1 There are two different subtypes of PD; 
one occurs in the nipple, which is called mammary Paget’s 
disease (MPD), and the other occurs in other sites and is 
better known as extramammary Paget’s disease (EMPD).1,2
The origin of the neoplasm is not yet entirely understood, 
and there are several hypotheses concerning the origin of 
Paget’s cells. Some authors suggest that EMPD has an 
intraepidermal origin from adnexal structures, specifically 
from apocrine glands2 or multipotent stem cells in the 
epidermal basal layer3. On the other hand, the origin of MPD 
is believed to originate from an intraductal cancer that has 
spread by upward migration to the nipple.4
PD predominantly affects white women between 50 
and 80 years old.5-7 Clinically, the disease presents as an 
erythematous well-demarked plaque, and the surface may 
have a scaly, grayish crust with erosion and ulceration. In 
some cases, pruritus and pain are found.4,7-11 The diagnosis 
is confirmed by a biopsy that presents a thickened epidermis, 
with papilomatosis, enlargement of the interpapillary ridges, 
hyperkeratosis or parakeratosis on the surface,11 and the 
characteristic Paget’s cells with a clear abundant cytoplasm.12 
The cytoplasm of those cels are Acid-Schiff stain (PAS) 
positive and diastase resistant, whch indicates the presence 
of neutral polysaccharides and supports the glandular origin 
of the cels.12 Staining with antibodies to carcinoembryonic 
antigen (CEA), low molecular weight cytokeratin (Cam 5.2), 
and cytokeratin 7 (CK7) are also positive, they are markers 
of glandular epithelium .3,4,8-10,12
MPD treatment is well established, as 80-98% of 
the cases are associated with ductal carcinoma. Surgical 
intervention is decided according to the oncological 
indication for the ductal carcinoma of the breast.8,9,13 It 
consists of the resection of the MPD with free margins.4,8-13 
The MPD prognosis is good, with a low recurrence 
rate.4,12,13,14
Even though the standard treatment for EMPD is also 
surgical, with intraoperatory margin control, the prognosis 
is not satisfactory, and there is a high recurrence rate.5,15,16 
For these reasons, new treatments, such as radiotherapy, 
CO2 laser, Imiquimod and others, are being investigated. 
However, none of them has shown to be effective for 
treatment in most cases.5-7,15
The objective of this study was to analyze the clinical 
evolution and interventions on patients with Paget’s disease 
followed in our ambulatory clinic between January 1991 and 
December 2007. 
CaSE DESCRIPTIONS
From January 1991 to December 2007, 14 patients were 
diagnosed with PD in our service. They represented 0.01% 
out of the total 114,646 patients registered in the department 
over the same period. Seven of these patients had MPD, and 
another seven patients had EMPD. 
All seven patients with MPD were Caucasian women. 
The mean age at diagnosis was 56.7 years (range 34-84 
years). The mean time between when the lesion was first 
noticed and the first consultation at our service was 3 years 
(range 1–4 years). All of these patients were investigated 
for underlying breast cancer. In five patients, invasive ductal 600
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carcinoma was diagnosed, one patient had an in situ ductal 
carcinoma, and one patient had no associated neoplasm. 
The six patients with breast cancer were investigated 
to determine the staging of the disease. The surgery was 
planned according to the oncological indication of the ductal 
carcinoma. In patients who underwent conservative surgery, 
such as quadrantectomy, the MPD was excised in the same 
surgery, with either a 1-2 cm margin or intraoperatory 
frozen-section of the margins. Treatment was also completed 
with radiotherapy or chemotherapy when indicated. No 
patients had recurrence after a mean follow-up time of 5 
years (range 2-10 years). 
Patient without breast cancer did not return for treatment 
and/or follow-up.
The seven patients with EMPD (Table 1) included three 
men and four women who were all Caucasians. The mean 
age at diagnosis was 68.4 years old (range 62-76 years). 
The women presented disease in the vulva, groin or perianal 
areas. Each man had a different compromised site; these sites 
included the scrotum, the penis and the axilla. The mean 
time between the initial lesion and the first consultation 
was 5.4 years (range 1-15 years). The six patients were 
previously treated in others hospitals with topical antifungals 
and corticosteroids, one of the patient did not remember the 
name of the medicaments that were previously used. None 
of them have had a therapeutic response.
All patients with EMPD underwent analysis of full blood 
cells count, renal function, hepatic enzymes, biochemical 
analysis and urinalysis. To complete the investigation of an 
occult neoplasm chest radiography, colonoscopy, abdominal 
and urinary tract ultrasound were made. Clinical assessments 
by a gastroenterologist and an urologist were provided. A 
clinical assessment by a gynecologist and mammography 
were performed for female patients. In none of the patients 
was internal neoplasm diagnosed.
Patient 1 was initially treated with radiotherapy 60 Gy 
in 30 fractions delivered via electrons. She had a complete 
response with clearing of the neoplasm (Figure 1). However, 
the EMPD recurred after 4 months. We then decided to 
excise the lesion with intraoperative frozen-section analysis 
of the margins. The histopathological study of the surgical 
sample showed compromised margins. For this reason, 
a complementary treatment with CO2 laser therapy was 
administered. The laser was applied at a power of 10-12W 
with a 2 mm spot, and it vaporized the area that was 1 cm 
beyond the visual margin of the lesion, layer-by-layer, until a 
depth of approximately 2 mm was reached. The patient had a 
complete response to the treatment, but she had a recurrence 
after 3 years. We then decided on surgical treatment with 
intraoperative frozen-section analysis of the margins. The 
patient was submitted to surgery in 2000 and 2001 with 
recurrence after 7 and 10 months, respectively. In 2002, 
she underwent another surgery without recurrence after 5 
years of follow-up. However, due to all the treatments, the 
patient had important anatomic and functional impairment, 
even after surgical reconstruction of the vulva. She has had 
a colostomy and needs a permanent vesical fold.
Patient 2 was also initially treated with radiotherapy 
with electrons, in a similar manner to the treatment for 
patient 1. She also had a complete response; however, after 
3 months, there was a recurrence of the neoplasm (Figure 2). 
She was submitted to Mohs micrographic surgery (MMS) 
with complete excision of the lesion with margins free from 
disease. After 7 years of follow-up, she had a recurrence. 
MMS treatment was provided again, and she has been 
without recurrence for 3 years now.
Table 1 - The clinical characteristics and treatments of the patients with EMPD
Patient 
No.
Age/Sex Location Size
(cm)
Treatment Recurrence
(months)
Response Follow-up 
(years
1 52/f Vulva 17 Radiotherapy
Vulvectomy
CO2 laser
Vulvectomy
4
12
36
7-10
CR
PR
CR
PR
17
2 71/f Inguino-crural 14 Radiotherapy
Mohs micrographic 
surgery
3
84
CR
CR
15
3 72/m Penis 7 Surgery 6-84 CR 17
4 68/m Axilla 8 Imiquimod
PDT
0 PR
PR
1
5 76/M Scrotum 5 PDT NA CR 0.5
6 73/F Vulva 10 PDT NA PR 0.5
7 67/F Vulva 20 PDT NA PR 0.5
CR - complete response (100% clearance); PR - partial response (50-99% clearance); MR - minimal response (< 50% clearance); NA - not applicable601
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Patient 3 was submitted to surgery in 1993 for a resection 
of a 1-cm margin. The histopathological study demonstrated 
that the margins were compromised. Because clinically, 
he did not present signs of the disease, we decided that the 
patient should be followed up for observation. In 2000, he had 
recurrence of the EMPD. Surgery with resection of a 1-cm 
margin was performed again. An analysis of the margin found 
that it was positive for neoplastic cells. He had a recurrence 
after 6 months. He was submitted to surgery with generous 
margins in 2001 and 2002; both had positive margins and led 
to recurrence of the EMPD after 6 and 9 months, respectively. 
In 2003, he was submitted to a new surgery with negative 
margins and has been free from disease for 4 years. 
Patient 4 was first treated with topical Imiquimod (5%) 
cream 5 times a week for a period of 6 months. After this 
period, the lesion has decreased in size by approximately 
50%. Then, he was started on treatment with photodynamic 
therapy (PDT), with 3 sections at 2 weeks intervals. The 
area that was treated was cleaned with saline (0.9%); then, 
topical aminolevulinic cream (16%, Metvix®) was applied 
on the lesion and extending 1 cm into the clinical disease-
free margins. The area was occluded for 3 hours. Then, it 
was cleaned with saline (0.9%) and exposed to 37 J/cm2 of 
visible red light. After 3 sessions were treated, a new biopsy 
was performed. The result was still positive for neoplastic 
cells. We decided that 5 more sessions were to receive PDT. 
This resulted in a 60% reduction of the lesion. However, the 
new biopsy still showed the presence of disease. The next 
plans are to surgically treat the patient.
Patients 5, 6 and 7 were treated with PDT using the 
same protocol as for patient 4. After the treatment of the 
first 3 sessions, they were also biopsied. Patient 5 showed 
no clinical or histopathological signs of the disease, with 
hypocromic residual macula (Figure 3). Patients 6 and 7 still 
had clinical and histopathological neoplasia; nevertheless, 
they had 40-60% reductions in their lesions and great 
Figure 1 - Before and after radiotherapy
Figure 2 - Before and after radiotherapy602
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improvement in the comfort level and quality of life (Figures 
4 and 5). They are both undergoing the protocol for 3 more 
sessions of PDT. 
DISCUSSION
Paget’s disease is a rare disease;5 in our ambulatory 
clinic, it represented only 0.01% of all registered patients 
over a 17-year period. In the literature, we were unable 
to find reports of the prevalence of PD in dermatology 
departments. 
Patients with MPD had characteristics that were 
similar to what has been described: age 50 to 80 years and 
Caucasian.2-5,8,9 
Even  though  the  clinical  and  histopathological 
characteristics of the MPD are well established, the patients 
Figure 3 - Before and after PDT
Figure 4 - Before and after treatment with PDT
Figure 5 - Before and after treatment with PDT603
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in our study had delays in the diagnosis, with a mean of 
3 years after the initial signs. This delay is detrimental to 
the patient because MPD is usually a sign of underlying 
breast cancer (invasive or in situ ductal carcinoma)4,5,8 and 
also because this tumor can precede the MPD by 1 to 2 
years.1,2,8,13 Consequently, this delay in the diagnosis may 
change the staging and prognosis of the patient.
Historically, patients with MPD have been submitted 
to more aggressive treatments8,10,13 because the invasive 
cancer associated with PD is more aggressive than those 
not associated with PD.8-10,13,14 Recently, however, large 
randomized studies with long-term follow-up have shown 
that conservative surgery is equivalent to radical mastectomy 
in terms of overall and disease-free survival in patients with 
breast cancer associated with MPD.4,13,14 For that reason, 
breast conservation, with removal of the nipple-areolar 
complex, is indicated for patients without a palpable mass 
or mammographic abnormality.8-10,13,14 Patients with a 
mammographic abnormality or a palpable mass should be 
candidates for breast conservative surgery with negative 
margins and evaluation of the lymph nodes.4,8 
In agreement with those data, the conservative approach 
used in our patients eradicated the tumors with no recurrence 
after a mean of 5 years of follow-up.
Thus, breast cancer in patients with MPD should be 
submitted to the same treatment given to breast cancer 
patients without MPD. The surgical treatment plan must 
be chosen on the basis of careful clinical and imaging 
assessment for each patient .4,8-10,13,14
There are reports of cases of MPD without breast cancer.8 
In our group, one of the seven patients was not diagnosed 
with breast cancer in the first evaluation, but it was not 
possible to confirm that she did not have an associated 
neoplasm because she did not have a follow up exam.
EMPD is rarer than MPD.7,15 In our study, however, we 
found the same number of patients in both groups. This 
identical incidence of MPD and EMPD that was found in 
our ambulatory was because patients with cutaneous breast 
lesions probably made visits to the gynecology department. 
Which falsely decreased the incidence of the MPD from 
dermatology departments. 
EMPD also more frequently affects white women, with 
a female-to-male ratio been 4:1 and a mean age of 65.5-7 
In our study, we confirmed these observations; all patients 
were Caucasian, and the mean age at diagnosis was 68.4 
years. On the other hand, there was no statistical difference 
between the number of affected men and women. However, 
we believe that women with vulvar lesions may have visited 
the gynecology department directly.
The most common sites of EMPD in women are the 
vulva and adjacent area. Men may present cutaneous lesions 
in the scrotum, penis, anus, perianal region and axillae(6,15). 
None of the patients had any uncommon sites or clinical 
presentations of the disease. However, the mean time for 
the diagnoses of the EMPD was 5.4 years. Furthermore, six 
patients were treated for eczema with topical corticosteroid 
and dermatophytosis with topical antifungal agents, without 
response. 
The delay in EMPD diagnosis may impair the prognosis 
of the patient because, even though EMPD is not typically 
associated with an underlying carcinoma,16 there have 
been reports of cases associated with urothelial, colorectal, 
endometrial, cervical and Bartholin’s gland cancer.5,16,17 The 
delay in the diagnoses will modify the staging and prognosis 
of the associated neoplasm. All of our patients were fully 
investigated for other cancers, and other cancers were not 
found in any of them. 
Furthermore, the delay in procuring and obtaining the 
appropriate treatment resulted in the patients’ lesions being 
advanced in spread, which also impaired the response to 
treatment and increased the recurrence rate.8,15
Another factor that is associated with poor prognosis 
in EMPD is having dermal invasion or metastasis via 
the lymphatic system.3,5,7,17 The invasion of the dermis is 
uncommon, and metastases are extremely rare. In most 
cases, Paget’s cells remain confined to the epidermis, and the 
prognosis is good.3,4,18 In particular, the prognosis is good in 
relation to mortality, as most of the patients will die from a 
pre-existing condition19 but not in relation to the disease.7,19
There is still no effective treatment for EMPD. 
Traditionally, the accepted first line of treatment, for either 
in situ or invasive EMPD, is surgical excision with generous 
margins.18-22 Nevertheless, surgery is associated with a 
high recurrence rate, between 31 and 61%.18,20 Another 
problem associated with this modality of treatment is the 
difficulty to close or to reconstruct the defects resulting 
from surgery. Because the lesion is usually in the anogenital 
and axillary area, surgery may lead to functional and sexual 
problems.15,21
With the aim to ensure a negative margin and to ensure 
that the skin be free from disease, we proposed surgery with 
intraoperative margin control,6,7,15,18 specifically, MMS.18,20,22 
Nonetheless, the recurrence rate reported is still 23-27%.18,21 
The high recurrence rate is attributed to the multifocal nature 
of the disease,6,7,15 and the high false negative margins rate 
of 43%.23-25 Furthermore, this surgery is also associated 
with the same problems of closing the wound and high 
morbidity.7,18,22
Patient 1 was submitted to surgery with frozen sections 
in 2000, 2001 and 2002, with a great area of resection, 
recurrence after the first 2 surgeries, and important 
impairment of the vulvar area. Patient 2 was submitted to 604
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MMS and had recurrence after living free of disease for 7 
years. Patient 3 was submitted to four surgeries with 1 to 2 
cm margins, with the first three surgeries having positive 
margins and recurrence. Our patients who were submitted to 
surgery, as described in the literature, presented with a high 
recurrence rate. Patient 1 also had an important anatomic and 
functional impairment. 
For these reasons, conservative approaches to EMPD 
have been studied, including radiotherapy, CO2 laser, topical 
Imiquimod 5% and, more recently, PDT.23-42
The role of radiotherapy is still not clear. Studies show 
good local control of the disease with minimal side effects. 
On the other hand, it also showed a recurrence rate greater 
than 80%.22 For these reasons, radiotherapy is usually 
used for patients who are unfit for surgery, for recurrence 
after excision, and for adjuvant treatment for surgery.24 
Radiotherapy with megavoltage photons, superficial x-rays, 
brachytherapy and electrons have better rates of local long-
term control.22-24
Because of the location and extent of the lesions, we 
proposed to treat patients 1 and 2 with radiotherapy with 
electrons. These patients showed a full response. However, 
both had recurrence of EMPD only 3-4 months after the 
treatment. Based on the literature, we expected a longer time 
free from disease after radiotherapy with electrons. 
Another alternative treatment studied was the CO2 
laser. PD is an intraepidermal neoplasm, the laser radiation 
vaporizes the epidermal layer, therefore the laser was to 
eliminate the neoplasm with preservation of the anatomy 
and function of the area.26,27 However, with a recurrence rate 
ranging from 31-67%, most of the patients complained about 
the pain both after the vaporization and for a long period 
afterwards.27 For this reason, the use of CO2 laser should be 
evaluated carefully for the suitability to each patient.
In patient 1, conservative treatment was associated with 
surgery, which included radiotherapy and CO2 laser, with the 
aim to preserve the function of the vulva area. The patient 
had recurrence after treatment. Thus, she was submitted to 
vulvectomy, but she had recurrence of the disease, and the 
new resections resulted in great impairment. 
More recently, a treatment with topical Imiquimod 
cream was reported.28-32 The Imiquimod (5%) cream is 
a topical imidazoquinoline immunomodulator that is a 
proinflammatory Toll-like receptor agonist that boosts the 
innate and acquired immune response.28 The patients were 
treated from 3 to 7 times each week for 6 to 17 weeks. 
Initial improvement was noted after 6 to 9 weeks. A 78% 
complete response to treatment without recurrence after 2 to 
12 months of follow-up was demonstrated.28-32 
Although those are promising reports of successful 
treatment with Imiquimod (5%), the use of this agent must be 
viewed with guarded optimism because the number of cases 
and the follow-up time are still small. Therefore, randomized 
controlled trials with long-term follow-up to determine the 
true safety and efficacy of Imiquimod compared with other 
therapy modalities for EMPD would be useful.28,32 In our 
experience with Imiquimod in patient 4, the lesion decreased 
by 50% after Imiquimod (5%) treatment five times a week 
for 24 weeks. However, this treatment was not satisfactory as 
it did not clear the neoplasm 6 month of treatment.
PDT is the most recent modality of therapy, and the 
reports to date have used 5-aminolevulinic acid 20% (ALA). 
The topical application of ALA leads to the biosynthesis and 
transient accumulation of the endogenous photosensitizer 
protoporphyrin IX (PpIX). ALA can diffuse in the skin and 
be preferentially accumulated in neoplastic cells. When a 
specific light wavelength is applied to the site, the light will 
be absorbed, and the energy will be transferred to molecular 
oxygen producing reactive singlet oxygen capable of causing 
direct cellular killing.40-42
There is still no consensus about the treatment with 
ALA-PDT in Paget’s disease. In previous reports, a topical 
application of ALA followed by occlusion, which varied 
from 3 to 18 hours, was proposed. Then ALA was removed, 
and the lesion was exposed to red light at 630 nm, with a 
light dose ranging from 37 to 200 J cm-2. The number of 
sections also varied from 3 to 10 sections.34-39 Complete 
remission was obtained in approximately 50%, and the 
recurrence was 37% in 10 months.34 In some cases, ALA-
PDT was associated with surgery.38
Patient 4 had a partial response with 8 sessions of PDT, 
and the treatment complemented with surgery. Patient 5 
had a complete response, has been free from disease after 3 
sessions and has been in remission for 3 months. Patients 6 
and 7 had partial responses to 3 sessions and are scheduled 
for 3 more sessions.
Photodynamic therapy is a promising treatment or 
adjuvant treatment that also needs further study with 
a randomized, well-controlled, long-term study for 
determining its function in the treatment of EMPD.
In conclusion, EMPD is an uncommon neoplasm without 
any effective treatment. The traditional surgical excision has 
a high recurrence rate and may result in aesthetic, anatomic 
and functional impairment. For this reason, conservative 
treatments such as topical Imiquimod cream and PDT 
have been studied recently. However, both treatments need 
further randomized, long-term studies to evaluate their 
effectiveness.605
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